The Ophthalmic Drugs Market Will Be Worth Over $37bn In 2026 Predicts New Visiongain Report

04 September 2018
Pharma

A new report by visiongain predicts that drugs to treat retinal disorders will remain the leading ophthalmic drug submarket to 2026. This forecast and others appear in Ophthalmic Drugs Market Forecast 2016-2026: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs, published in July 2016. Visiongain is a business information provider based in London, UK.

Ophthalmic Drugs Market Forecast 2016-2026 report examines the current and future trends for submarkets and companies in the ophthalmic drugs market.

In 2013, the World Health Organization (WHO) estimated the number of people with visual impairment at 285 million, of which 39 million were blind and 246 million had low vision. Blindness and visual impairment disproportionately affect older people; for example, 82% of all blind people are aged 50 years or older. This means that with a burgeoning elderly population globally, the number of people affected by visual impairment is set to increase rapidly.

The ophthalmic drugs market consists of those pharmaceuticals – both prescription and over-the-counter or OTC – which address the diseases and eye conditions that lead to visual impairment, as well as eye conditions of importance for other reasons. There is also a greater impact of eye disease in developing countries including the emerging markets of China and India. This makes understanding the ophthalmic drugs market, the leading companies in the market and the opportunities available is crucial for all those in fields related to the sector.

In this report, we examine are the sales of a wide range of ophthalmic drugs in the following submarkets: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs and Dry Eye Drugs. An analysis of 25 major drugs, with 10-year forecasts and upcoming pipeline candidates in the sector are also included for all of the major submarkets, along with analysis and forecasts for all major submarkets in the ophthalmic drugs market.

Current leading players in the ophthalmic drugs market are also analysed, with 10-year ophthalmic drug revenue forecasts. Also given is a breakdown of each company’s leading products, leading pipeline candidates and recent merger & acquisition information, with analysis of news that may influence the course of the company. Analyses of promising pipeline candidates which may enter the market over the forecast period are also included.

Matteo Bianchi, a pharmaceutical and medical devices industry analyst in visiongain, said: The ophthalmic drugs market remains an attractive niche market for pharmaceutical companies despite the level of generic competition that has been faced by a number of leading products in the market over the past few years. Although generic competition has reduced revenue for a number of products, the market has experienced growth across most segments, with a high level of both M&A and R&D activity to bring products to the market for various ophthalmic indications. The ageing global population will lead to an increasing prevalence of ophthalmic conditions, many of which are associated with old age, contributing to the growth that will be seen over the next 10 years. The rise of novel therapies such as RNA interference technologies, gene therapies and combination drug/device products will couple with improving support for reimbursement in the ophthalmic drug market will also drive growth across the forecast period. However difficulties with patient adherence and the rising cost of R&D may hinder growth within this market.”
Visiongain’s report provides revenue forecasts to 2026 for the ophthalmic drugs market and its leading submarkets, drugs and companies. The report discusses leading companies which hold significant shares of the market in depth. These companies include Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer and Senju. Visiongain’s report also discusses key economic points, commercial news, and analysis of strengths, weaknesses, opportunities and threats.

Ophthalmic Drugs Market Forecast 2016-2026: Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

“Pharmaceutical Contract Manufacturing market set to grow to $138bn by 2024” says new Visiongain report

The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.

19 August 2019

Read

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever